Amsurg Corp. (NASDAQ:AMSG) was upgraded by Wells Fargo & Co. from a “market perform” rating to an “outperform” rating in a research report issued on Wednesday. The analysts noted that the move was a valuation call.
Several other research analysts also recently weighed in on the company. KeyCorp reiterated a “positive” rating and issued a $87.00 target price on shares of Amsurg Corp. in a research note on Tuesday, October 4th. Citigroup Inc. assumed coverage on Amsurg Corp. in a research note on Monday, September 26th. They issued a “buy” rating and a $79.00 target price on the stock. Zacks Investment Research downgraded Amsurg Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $95.00 target price on shares of Amsurg Corp. in a research note on Thursday, July 14th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Amsurg Corp. presently has an average rating of “Buy” and an average price target of $89.45.
Shares of Amsurg Corp. (NASDAQ:AMSG) traded up 0.71% during mid-day trading on Wednesday, reaching $66.22. The company’s stock had a trading volume of 296,468 shares. The company’s 50-day moving average is $64.34 and its 200 day moving average is $70.20. The firm has a market capitalization of $3.56 billion, a P/E ratio of 20.44 and a beta of 0.67. Amsurg Corp. has a 1-year low of $57.32 and a 1-year high of $86.17.
Amsurg Corp. (NASDAQ:AMSG) last announced its earnings results on Tuesday, November 1st. The company reported $1.13 earnings per share for the quarter, meeting the consensus estimate of $1.13. Amsurg Corp. had a return on equity of 8.05% and a net margin of 6.06%. The company had revenue of $822.20 million for the quarter, compared to the consensus estimate of $770.29 million. During the same period last year, the business posted $1.03 EPS. The company’s revenue was up 26.5% on a year-over-year basis. On average, analysts expect that Amsurg Corp. will post $4.31 earnings per share for the current year.
Institutional investors have recently modified their holdings of the company. Emerald Acquisition Ltd. bought a new position in Amsurg Corp. during the second quarter worth $106,000. Rockefeller Financial Services Inc. bought a new position in Amsurg Corp. during the third quarter worth $106,000. Smith Asset Management Group LP boosted its position in Amsurg Corp. by 8,500.0% in the second quarter. Smith Asset Management Group LP now owns 1,720 shares of the company’s stock worth $133,000 after buying an additional 1,700 shares during the period. Acrospire Investment Management LLC boosted its position in Amsurg Corp. by 46.2% in the third quarter. Acrospire Investment Management LLC now owns 1,900 shares of the company’s stock worth $127,000 after buying an additional 600 shares during the period. Finally, Invictus RG boosted its position in Amsurg Corp. by 824.3% in the first quarter. Invictus RG now owns 1,904 shares of the company’s stock worth $142,000 after buying an additional 1,698 shares during the period. 98.67% of the stock is owned by hedge funds and other institutional investors.
Amsurg Corp. Company Profile